Trials Test Tighter Blood Pressure Goals in Chicago
Stroke survivors and adults with type 2 diabetes will see first results from intensive blood pressure trials at the November 2026 meeting.
Updated on Nov. 6, 2026 in Diseases

The American Heart Association's scientific sessions in Chicago, November 7-9, 2026, will feature late-breaking trials on intensive blood pressure control, statin discontinuation, and related heart-risk therapies. Expanded programming begins November 6, and select sessions will be livestreamed for readers in the Chicago area and beyond.
Why it matters
The OPTIMAL trials test whether a systolic blood pressure target below 120 mmHg is beneficial for people who have had a stroke or have type 2 diabetes, groups that were excluded from the earlier SPRINT trial. The STREAM trial will examine whether older adults without cardiovascular disease can safely stop statins, a question that bears directly on prevention and long-term medication decisions.
These are late-breaking randomized trials, with results to be presented at the November 2026 meeting rather than already published. The OPTIMAL studies focus on blood pressure targets in stroke survivors and higher-risk diabetes patients, while STREAM is a randomized noninferiority trial of statin discontinuation in older adults without cardiovascular disease.
The players
American Heart Association
The leading U.S. nonprofit focused on heart disease and stroke research, education, and prevention, which hosts this scientific meeting.
SPRINT trial
A landmark National Institutes of Health-funded study that established intensive blood pressure control as a strategy to reduce cardiovascular events.
The details
The OPTIMAL trials compare an intensive systolic blood pressure goal of less than 120 mmHg against standard care, enrolling participants whose starting pressure falls between 130 and 180 mmHg. OOPTIMAL-Stroke enrolls ischemic stroke survivors, while OPTIMAL-Diabetes enrolls higher-risk adults with type 2 diabetes, populations the SPRINT trial did not include. STREAM asks whether stopping statins is no worse than continuing them in older adults, a noninferiority design that tests whether the discontinued arm performs acceptably. The meeting will also present ZEUS, which reports cardiovascular outcomes for the interleukin-6 blocker ziltivekimab.
Timeline
Nov. 6, 2026: Expanded AHA programming begins in Chicago.
Nov. 7-9, 2026: AHA main scientific sessions take place in Chicago.
Sat., Nov. 7, 2026: OPTIMAL-Stroke and OPTIMAL-Diabetes late-breakers are presented.
Sun., Nov. 8, 2026: OptimPacing and SUPERIOR trials are presented.
Mon., Nov. 9, 2026: ATTAIN-OSA and WATCH-LV trials are presented.
Health Landscape
The OPTIMAL studies are designed to fill gaps left by the SPRINT trial, which excluded ischemic stroke survivors and people with type 2 diabetes. Together with the STREAM statin trial, they test whether the intensive-control and deprescribing approaches that have shaped prevention guidance hold up in higher-risk and older populations.
If you have high blood pressure, a history of stroke, or type 2 diabetes, these trials may eventually inform how blood pressure targets are set for people like you, so it is worth discussing your current goals with your physician. Adults taking statins should not change their medication on the basis of these results alone; any question about continuing or stopping therapy belongs in a conversation with your doctor.
The takeaway
Results from these trials will show whether intensive blood pressure control and statin discontinuation hold up in populations that prior research did not cover. Watch for the November 2026 presentations, and bring any questions about blood pressure targets or statin use to your physician.
What happens next
The OPTIMAL, STREAM, and related trial results are scheduled for presentation on November 7-9, 2026, in Chicago.
Further reading
For background on the research behind these trials, explore our Heart Disease coverage.
Source note: This article includes information reported by MedPage Today.




